Image may be NSFW.
Clik here to view.
GlaxoSmithKline (LON:GSK)‘s stock had its “underperform” rating reaffirmed by equities research analysts at BNP Paribas in a research note issued to investors on Thursday, Stock Ratings Network reports. They currently have a GBX 1,500 ($22.89) price target on the stock. BNP Paribas’ target price points to a potential downside of 10.98% from the company’s current price.
A number of other firms have also recently commented on GSK. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday. They now have a GBX 1,710 ($26.10) price target on the stock. Separately, analysts at Barclays Capital reiterated an “overweight” rating on shares of GlaxoSmithKline in a research note to investors on Monday. They now have a GBX 1,610 ($24.57) price target on the stock. Finally, analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, July 18th. They now have a GBX 2,000 ($30.53) price target on the stock.
Six investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company. GlaxoSmithKline currently has a consensus rating of “Hold” and a consensus target price of GBX 1,732.98 ($26.45).
GlaxoSmithKline (LON: GSK) traded down 1.34% on Thursday, hitting GBX 1662.50. GlaxoSmithKline has a 52-week low of GBX 1314.00 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is currently GBX 1437.31. The company’s market cap is £80.532 billion.
GlaxoSmithKline plc (LON: GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.Image may be NSFW.
Clik here to view.
